Clinical Trials
10
Active:0
Completed:10
Trial Phases
3 Phases
Phase 1:1
Phase 3:2
Phase 4:5
Drug Approvals
3
FDA:3
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 4
5 (62.5%)Phase 3
2 (25.0%)Phase 1
1 (12.5%)Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 148
- Registration Number
- NCT01167426
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT01049984
- Locations
- 🇺🇸
Teva Investigational Site 34, Phoenix, Arizona, United States
🇺🇸Teva Investigational Site 42, Sun City, Arizona, United States
🇺🇸Teva Investigational Site 15, Fountain Valley, California, United States
Therapy Optimization in Multiple Sclerosis (MS)
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 2878
- Registration Number
- NCT00819000
- Locations
- 🇺🇸
Teva Investigational Site, Carnegie, Pennsylvania, United States
A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency
Phase 1
Completed
- Conditions
- Growth Hormone Deficiency
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2013-09-02
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00455260
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Phase 4
Completed
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00399477
- Prev
- 1
- 2
- Next
News
No news found